




# PHARMACEUTICAL 2023

INTERCEPT PHARMACEUTICALS  
INC.  
Rank 231 of 446





# PHARMACEUTICAL 2023

## INTERCEPT PHARMACEUTICALS INC. Rank 231 of 446



The relative strengths and weaknesses of INTERCEPT PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTERCEPT PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 130% points. The greatest weakness of INTERCEPT PHARMACEUTICALS INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 75%, being 32% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	540,127
Cost of Goods Sold	984
Intangible Assets	0
Liabilities, Current	230,077
Liabilities, Non-Current	230,557
Other Assets	12,597
Other Compr. Net Income	-5,383
Other Expenses	0
Other Liabilities	0
Other Net Income	290,032
Other Revenues	285,710
Property and Equipment	987
Research and Development	176,639
Selling, General and Administrative Expense	176,303

Output Variable	Value in 1000 USD
Assets	553,711
Liabilities	460,634
Expenses	353,926
Revenues	285,710
Stockholders Equity	93,077
Net Income	221,816
Comprehensive Net Income	219,124
Economic Capital Ratio	75%